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BACKGROUND: A single-arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T-cell–engaging anti-
body construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), 
a rare hematologic malignancy with limited treatment options. This study compared outcomes with blinatumomab with those of a 
historical control treated with the standard of care (SOC). METHODS: The blinatumomab trial enrolled adult patients with Ph+ ALL 
who were r/r to at least 1 second-generation tyrosine kinase inhibitor (n = 45). Propensity score analysis (PSA) was used to compare 
outcomes with blinatumomab with those of an external cohort of similar patients receiving SOC chemotherapy (n = 55). The PSA miti-
gated confounding variables between studies by adjusting for imbalances in the age at diagnosis and start of treatment, sex, duration 
from diagnosis to most recent treatment, prior allogeneic hematopoietic stem cell transplantation, prior salvage therapy, and number 
of salvage therapies. Bayesian data augmentation was applied to improve power to 80% with data from a phase 3 blinatumomab study 
in r/r Philadelphia chromosome–negative ALL. RESULTS: In the PSA, the rate of complete remission or complete remission with partial 
hematologic recovery was 36% for blinatumomab and 25% for SOC, and this resulted in an odds ratio of 1.54 (95% confidence interval 
[CI], 0.61-3.89) or 1.70 (95% credible interval [CrI], 0.94-2.94) with Bayesian data augmentation. Overall survival favored blinatumomab 
over SOC, with a hazard ratio of 0.81 (95% CI, 0.57-1.14) or 0.77 (95% CrI, 0.61-0.96) with Bayesian data augmentation. CONCLUSIONS: 
These results further support blinatumomab as a treatment option for patients with r/r Ph+ ALL. Cancer 2020;126:304-310. © 2019 The 
Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms 
of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided 
the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
KEYWORDS: blinatumomab, Philadelphia chromosome–positive acute lymphoblastic leukemia, propensity score analysis, remission, 
standard of care, survival.
INTRODUCTION
The development of BCR-ABL1 protein–specific tyrosine kinase inhibitors (TKIs) has significantly improved outcomes 
in Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).1-3 The standard of care (SOC) for 
de novo Ph+ ALL is induction with conventional or attenuated chemotherapy in combination with a TKI.2,3 Most 
patients achieve complete remission (CR) and proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT).4 
However, relapse can occur and is commonly associated with TKI-resistant mutations in the kinase domain of the 
BCR-ABL1 oncogene.5 There is no definitive evidence of a sustained response or long-term survival with TKIs after 
a relapse, with overall survival (OS) ranging from approximately 4 to 6 months.4,6,7 Compounding these challenges, 
Ph+ ALL is rare,8 and this limits most clinical trials evaluating new treatments to single-arm studies.2,3
Blinatumomab is a bispecific T-cell–engaging antibody construct that binds simultaneously to CD3-positive cytotoxic 
T cells and CD19-positive B cells and allows endogenous T cells to recognize and eliminate CD19-positive ALL blasts.9 
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Prior studies have established the efficacy and safety of 
blinatumomab in relapsed/refractory (r/r) Philadelphia 
chromosome–negative (Ph–) ALL.10 Both Ph– and Ph+ 
B-precursor leukemic cells express CD19; therefore, bli-
natumomab was assessed in a single-arm, phase 2 study 
of patients with r/r Ph+ ALL who had received a sec-
ond-generation TKI.11 Of the 45 patients enrolled, 36% 
achieved CR or complete remission with partial hemato-
logic recovery (CRh). The median OS was 7.1 months.
To assess the relevance of the blinatumomab study 
results within the wider context of available treatment 
options, we compared the treatment outcomes with those 
of an external control population. For rare diseases with-
out a satisfactory SOC, regulatory agencies support the 
use of external controls as a method for demonstrating 
the efficacy of new treatments.12 A problem with this 
approach is the substantial variability among patients 
in the external control cohort. Propensity score analysis 
(PSA) provides a better balance between patients receiv-
ing the treatment of interest and the external control with 
respect to relevant baseline factors, and it enables a less 
biased comparison of outcomes.
Here we report the results of a PSA comparing ef-
ficacy data from the phase 2 blinatumomab study and 
those of an external population: patients with r/r Ph+ 
B-precursor ALL who had received SOC after the failure 
of or resistance to treatment with second-generation TKIs.
MATERIALS AND METHODS
External SOC
The external SOC cohort was identified and developed 
from existing clinical databases at centers in Italy (Pope 
John XXIII Hospital [Bergamo] and Sant’Orsola Policlinic 
[Bologna]) and Spain (Josep Carreras Research Institute, 
Hospital Germans Trias i Pujol, Catalan Oncology Institute 
[Barcelona]). To align with the eligibility criteria of the phase 
2 blinatumomab trial, patients with r/r Ph+ ALL included 
in the external SOC cohort were 18 years old or older, were 
r/r to at least 1 second-generation TKI (dasatinib, nilotinib, 
bosutinib, or ponatinib), and had >5% bone marrow blasts. 
Patients were excluded if they had a history of malignancy 
other than ALL within 5 years of initiating salvage SOC, 
central nervous system or extramedullary disease, or prior 
therapy with blinatumomab. There were no restrictions on 
qualifying salvage therapy.
Data collection began in August 2017 and ended in 
January 2018. Fifty-five patients met all eligibility criteria 
and were included in the current analysis (see Supporting 
Fig. 1). The baseline period started from the initial di-
agnosis of ALL and ended at the start of the qualifying 
salvage therapy, and data were collected from diagnosis 
until the date of death or last follow-up. Investigators 
received approval from an institutional review board or 
ethics committee of participating centers.
Blinatumomab Ph+ ALL study
The blinatumomab study was an open-label, single-
arm, multicenter, phase 2 clinical trial of blinatumomab 
in adults with r/r Ph+ ALL (ClinicalTrials.gov iden-
tifier NCT02000427). The study was conducted at 
19 centers in Europe and the United States. Details of this 
study have been previously reported.11 Patients with Ph+ 
B-precursor ALL who were 18 years old or older were 
eligible for enrollment provided that they were r/r to at 
least 1 second-generation TKI, had >5% bone marrow 
blasts, and had an Eastern Cooperative Oncology Group 
performance status of 2 or lower. Exclusion criteria in-
cluded allo-HSCT within the 12 weeks before the start of 
blinatumomab, active acute or chronic (grade 2-4) graft-
versus-host disease, systemic treatment of graft-versus- 
host disease within 2 weeks of starting blinatumomab, a 
history or presence of clinically relevant central nervous 
system pathology (including central nervous system ALL), 
isolated extramedullary disease, and a history of malig-
nancy other than ALL within 5 years. Blinatumomab was 
administered as a continuous intravenous infusion at a 
dose of 9 µg/d in week 1 of cycle 1 and at a dose of 28 µg/d 
thereafter. For each treatment cycle, blinatumomab was 
administered for 4 weeks, which was followed by 2 weeks 
off treatment. Patients who achieved CR/CRh could 
receive up to 3 additional cycles of treatment. The base-
line period for patients began in January 2014, and the 
study ended in May 2015. All patients provided informed 
consent, and the study was approved by the institutional 
review boards of participating centers.
Efficacy Endpoints
Efficacy endpoints for the PSA included OS and CR/CRh. 
For time-to-event analyses, patients were followed from 
the start date of blinatumomab or SOC therapy to the 
event or were censored at the time they were lost to 
follow-up or alive. CR was defined as ≤5% bone mar-
row blasts, with a platelet count >100,000/μL, an 
absolute neutrophil count >1000/μL, and no evidence of 
extramedullary disease. CRh was defined as ≤5% bone 
marrow blasts, with a platelet count >50,000/μL and an 
absolute neutrophil count >500/μL. The response was 
determined within the first 2 treatment cycles in the bli-
natumomab study (approximately 70 days) but varied for 
the SOC cohort with the treatment (the median time to a 
response was 48 days).
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Propensity Score Analysis
The PSA was planned and prespecified before endpoint 
analyses were conducted. The PSA created a balance 
between the blinatumomab and external SOC cohorts 
with respect to available baseline covariates that deter-
mined both the propensity for a patient to be treated 
(with blinatumomab) and a patient’s prognosis.13-15 The 
baseline covariates included the age at diagnosis and 
treatment, sex, time from diagnosis to most recent treat-
ment (months), prior allo-HSCT status (yes or no), prior 
salvage therapy status (yes or no), and number of prior 
salvage therapies (0, 1, 2, 3, or ≥4). An estimated propen-
sity score (ie, the predicted probability of participating 
in the blinatumomab phase 2 trial) was assigned to each 
patient on the basis of the selected covariates. The balance 
of covariates between patients in the blinatumomab trial 
and patients in the external cohort was determined by the 
calculation of standardized differences in each covariate 
before and after propensity score adjustments and box 
plot overlap in propensity scores.
In the estimation of treatment effects, propensity 
scores were used to adjust for differences between patients 
in the blinatumomab and external SOC cohorts via in-
verse probability of treatment weighting (IPTW) meth-
ods.16 The objective was to estimate the average treatment 
effect (ATE) from moving the entire population from an 
untreated status to a treated status.17 Sensitivity analyses 
explored the use of stabilized inverse probability of treat-
ment weighting (sIPTW), which accounts for potential 
instability caused by very large weights,18 and the average 
treatment effect of treated weights (ATT).19 Covariates 
with a standardized difference >0.20 after IPTW adjust-
ment were added to statistical models as covariates.
CR/CRh rates were analyzed with a logistic regres-
sion model with a single-treatment indicator covariate and 
propensity score–based weights to adjust for differences 
between the blinatumomab and external SOC cohorts. 
The model’s coefficient for treatment effect was used to 
obtain an odds ratio, and a robust variance estimation 
(applied with a generalized estimating equation) was used 
to construct 95% confidence intervals (CIs) to evaluate 
the probability of CR/CRh. Similarly, OS was analyzed via 
a Cox proportional hazards model with a single-treatment 
indicator covariate and with propensity score–based 
IPTW or sIPTW weights to adjust for differences.
Because of the small sample sizes, the PSA had a sta-
tistical power of 65% to detect an assumed hazard ratio 
of 0.75 favoring blinatumomab treatment. To increase 
power, Bayesian data augmentation was applied to end-
point analyses using distributions of OS and the odds 
ratio of CR/CRh from the phase 3 trial of blinatumomab 
versus SOC in patients with r/r Ph– B-cell precursor 
ALL.10,20 For Bayesian models, point estimates and 95% 
credible intervals (CrIs) were estimated with summary 
statistics and the relative highest posterior density inter-
val of the posterior distributions for model parameters of 
interest. Bayesian models used enough “borrowing” from 
the phase 3 trial to achieve a power of 80%. Potential bias 
was assessed by the completion of sensitivity analyses with 
prespecified lower levels of borrowing (ie, power levels of 
70% and 75%). Statistical programming was conducted 
in SAS 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
Patient characteristics are presented in Table 1. All but 
1 patient in each of the cohorts were enrolled on the basis 
of r/r Ph+ ALL to a second-generation TKI. One patient 
in the external SOC cohort was intolerant to a second- 
generation TKI and had failed or was intolerant to 
imatinib, whereas 1 patient in the blinatumomab cohort 
was resistant to imatinib but had not received a second-
generation TKI (protocol deviation).
The study populations were generally similar with 
respect to sex and age, but differences were noted for geo-
graphic region and prior treatments. The proportion of 
patients with no prior salvage therapy was higher in the 
blinatumomab cohort (13% vs 31%), as were the pro-
portions with prior treatment with 3 or more TKIs (16% 
vs 38%) and prior allo-HSCT (33% vs 44%). Dasatinib 
was the most common prior TKI in both cohorts (89% vs 
87%). Prior treatment with imatinib was more common 
in the external SOC cohort (87% vs 56%), whereas prior 
treatment with ponatinib was more common in the blina-
tumomab cohort (13% vs 51%).
Qualifying salvage therapies in the external SOC 
cohort included chemotherapy (22%), chemotherapy 
plus a TKI (29%), and a TKI alone (31%; see Supporting 
Table 1). Common chemotherapy agents included mer-
captopurine, vincristine, cytarabine, cyclophosphamide, 
and mitoxantrone. Generally, chemotherapy included 
combination regimens such as high-dose cytarabine and 
mitoxantrone (HAM), mitoxantrone, etoposide, and 
cytarabine (MEC), and cyclophosphamide, vincristine, 
doxorubicin, and dexamethasone (hyper-CVAD). Other 
treatments (18%) included an aurora kinase inhibitor, 
bortezomib, and donor leukocyte infusion, used alone 
or as part of a combination chemotherapy regimen, 
and salvage allo-HSCT. Use of corticosteroids was com-
mon. Fifteen patients (27%) in the external SOC cohort 
achieved CR/CRh with their qualifying salvage therapy, 
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with 14 (25%) achieving CR and 1 (2%) achieving CRh 
(Table 2). For the 51 patients for whom OS data were 
available, the median OS was 6.0 months (95% CI, 
4.4-9.2 months; Supporting Fig. 2).
The primary analysis of the blinatumomab study 
has been previously reported.11 The CR/CRh rate was 
36% after 2 cycles, with 14 patients (31%) achieving CR 
and 2 patients (4%) achieving CRh. The median OS was 
7.1 months (95% CI, 5.6 to not estimable).
Propensity Score Analysis
All propensity scores for the external SOC control were 
contained within the 95% range of the propensity scores 
for blinatumomab, and this indicated that most patients 
in the external SOC would have been eligible to re-
ceive blinatumomab treatment (Supporting Fig. 3). Two 
covariates had a >0.20 standardized difference between 
the cohorts: prior allo-HSCT and no prior salvage ther-
apy (Supporting Table 2). After adjustments with IPTW, 
the standardized difference became 0 for no prior salvage 
therapy and was reduced from –0.33 to –0.23 for prior 
allo-HSCT. Because the difference remained >0.20, the 
propensity score models incorporated an IPTW-ATE 
adjustment with prior allo-HSCT as a covariate.
The Bayesian-augmented (80% power) odds ratio 
estimate for CR/CRh was 1.70 (95% CrI, 0.94-2.94) and 
favored blinatumomab over the external SOC (Table 3). 
Corresponding CR/CRh rate estimates for the blinatu-
momab and external SOC cohorts were 36% (95% CrI, 
28%-46%) and 25% (95% CrI, 17%-34%), respectively. 
The non-Bayesian (65% power) odds ratio was 1.54 
(95% CI, 0.61-3.89).
The Bayesian-augmented (80% power) hazard ratio 
comparing the OS of blinatumomab with the OS of the 
external SOC was 0.77 (95% CrI, 0.61-0.96), and this 
suggested a statistically significant 23% reduction in the 






Age, median (range), ya 53 (20-82) 55 (23-78)
Age category, No. (%)a 
18-34 y 9 (16) 5 (11)
35-54 y 22 (40) 17 (38)
≥55 y 24 (44) 23 (51)
Sex, No. (%)
Male 28 (51) 24 (53)
Female 27 (49) 21 (47)
Geographic region/country, No. (%)
United States 0 11 (24)
European Union 55 (100)b 34 (76)
Lines of prior salvage treatment, 
No. (%)
0 7 (13) 14 (31)
1 31 (56) 12 (27)
≥2 17 (31) 19 (42)
No. of prior TKI treatments, No. (%)
1 6 (11) 7 (16)
2 41 (75) 21 (47)
≥3 8 (15) 17 (38)
Prior TKIs, No. (%)a 
Imatinib 48 (87) 25 (56)c 
Dasatinib 49 (89) 39 (87)
Ponatinib 7 (13) 23 (51)
Nilotinib 10 (18) 16 (36)
Multiple TKIs 49 (89) 38 (84)
Prior allo-HSCT, No. (%)
Yes 18 (33) 20 (44)
No 37 (67) 25 (56)
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; 
SOC, standard of care; TKI, tyrosine kinase inhibitor.
aBefore the start of qualifying salvage therapy for the external SOC cohort.
bSpain (n = 14) and Italy (n = 41).
cOne patient had acute lymphoblastic leukemia resistant to imatinib and was 
never exposed to a second-generation or later TKI.





Response to treatment, No. (%)a 
Overall complete remission 15 (27) 16 (36)
Complete remission 14 (25) 14 (31)
Complete remission with  
partial hematologic recovery
1 (2) 2 (4)
Complete remission with i 
ncomplete hematologic recovery
1 (2) 2 (4)
Blast-free hypoplastic or  
aplastic bone marrow
NA 3 (7)
Partial remission 1 (2) 2 (4)
No response NA 12 (27)
Refractory/progressive disease/
early death
28 (51) 4 (9)
Unknown/missing 10 (18) 6 (13)
Proceeded to allo-HSCT, No. (%) 8 (15) 4 (9)
Overall survival, median  
(95% CI), mo
6.0 (4.4-9.2)b 7.1 (5.6 to NE)
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; 
CI, confidence interval; NA, not available; NE, not estimable; SOC, standard 
of care.
aResponse within the first 2 cycles of treatment for the blinatumomab study.
bOverall survival data were available for 51 patients (4 were missing the treat-
ment start or last follow-up date).
TABLE 3. Summary of CR/CRh Analysis With and 







Non-Bayesian data  
augmentation (65% power)
OR, 1.54 (95% CI, 0.61-3.89); P = .26
CR/CRh, % (95% CI) 26 (16-40) 36 (22-52)
Bayesian data augmentation 
(80% power)
OR, 1.70 (95% CrI, 0.94-2.94); P = .076
CR/CRh, % (95% CrI) 25 (17-34) 36 (28-46)
Abbreviations: ATE, average treatment effect; CI, confidence interval; CR, 
complete remission; CRh, complete remission with partial hematologic re-
covery; CrI, credible interval; IPTW, inverse probability of treatment weighting; 
OR, odds ratio; SOC, standard of care.
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risk of death associated with blinatumomab in compar-
ison with the external SOC. The non-Bayesian (65% 
power) hazard ratio was 0.81 (95% CI, 0.57-1.14; Table 4 
and Fig. 1).
Sensitivity analyses of less borrowing for Bayesian 
data augmentation were consistent with these analyses 
(see Supporting Table 3 [CR/CRh] and Supporting Fig. 4 
[OS]), as were ATT sensitivity analyses (Supporting 
Tables 4 [CR/CRh] and 5 and Supporting Figs. 4 and 5 
[OS]) and sIPTW analyses (Supporting Fig. 6 [OS]).
DISCUSSION
In the single-arm, phase 2 blinatumomab trial, adult 
patients with r/r Ph+ ALL receiving blinatumomab 
achieved a CR/CRh rate of 36% with a median OS of 
7.1 months.11 These results suggested an improvement in 
treatment outcomes with blinatumomab in comparison 
with historical studies but were limited by the single-arm 
trial design.4,6,7 In the current analysis, PSA places these 
efficacy results into the context of available treatment 
options. By aligning the eligibility criteria of the external 
SOC with those of the blinatumomab study, we selected 
a similar patient population for comparison. Both patient 
populations were heavily pretreated and balanced for 
most baseline covariates. In the external SOC group, the 
CR/CRh rate was 26%, and the median OS was 6.0 months; 
this was consistent with historical Ph+ ALL studies.4,6,7
PSA, adjusted for imbalances in prognostic covariates 
and Bayesian data augmentation, was applied to improve 
statistical power. Bayesian-augmented PSA demonstrated 
a 70% increase in the odds of achieving remission with 
blinatumomab in comparison with the external SOC, a 
numerical benefit that did not reach statistical significance. 
The Bayesian-augmented analysis of OS showed a statisti-
cally significant 23% decrease in the hazard of death with 
blinatumomab treatment in comparison with SOC, and 
sensitivity analyses were consistent with these findings. For 
future salvage treatment strategies, these observations will 
be of great importance, particularly among patients for 
whom allo-HSCT is planned only in second remission.21,22
Although safety data for the external SOC were not 
available for comparison, treatment toxicity is a relevant 
concern. During the phase 2 blinatumomab study, all 
patients experienced at least 1 treatment-emergent adverse 
event (AE), and 82% experienced a grade 3 or higher AE, 
but these were generally manageable because only 7% 
of the patients discontinued treatment on account of an 
AE.11 The most common grade 3 or higher AEs included 
febrile neutropenia (27%), thrombocytopenia (22%), 
and anemia (16%). One fatal AE (septic shock) was con-
sidered treatment-related by the investigator. Overall, bli-
natumomab was tolerable with manageable AEs.
Given the benefit-to-risk profile of blinatumomab 
in the phase 2 trial and across clinical trials in ALL,10,11  
future studies are looking to pair blinatumomab with TKIs 
because the combination may provide additional bene fit 
to patients with Ph+ ALL.23 There is also evidence in 
Ph– ALL to support the use of blinatumomab in patients 
at earlier stages of treatment, including patients who have 
achieved CR/CRh with induction therapy but still have 
minimal residual disease (MRD).10,24 In the phase 2 trial, 
18 of 45 patients with r/r Ph+ ALL who received blina-
tumomab achieved an MRD response, with the median 
OS not reached for MRD responders versus 3.9 months 
for MRD nonresponders.11 MRD response data were not 
available for all patients in the external SOC cohort, so a 
comparison was not possible.
PSA has become an established method to support 
the development of novel treatments for rare malignan-
cies.12,25 However, there are limitations. Although PSA 
mitigates the impact of known confounders and bias, it 
is not a replacement for randomization. In the propen-
sity score model, one can consider only known covariates 
that are measured in both studies. The use of PSA cannot 
address imbalances in unmeasured/unknown covariates 
or postbaseline variables. For the external SOC cohort, we 
did not have data for some of the eligibility criteria that 
defined the blinatumomab study population (eg, prior 
graft-versus-host disease, duration of remission with prior 
allo-HSCT, and Eastern Cooperative Oncology Group 
performance status) or data for other important prognostic 
TABLE 4. Summary of OS Analysis With and 







HR, 0.81 (95% CI, 0.57-1.14); P = .20
OS probability, % (95% CI)
3 mo 79 (70-89) 83 (74-93)
6 mo 52 (40-68) 59 (47-74)
9 mo 39 (27-57) 47 (35-64)
12 mo 32 (20-50) 40 (28-57)
Bayesian data augmentation 
(80% power)
HR, 0.77 (95% CrI, 0.61-0.96); P = .031
OS probability, % (95% CrI)
3 mo 79 (77-81) 83 (82-85)
6 mo 51 (47-55) 60 (57-63)
9 mo 39 (34-43) 48 (44-52)
12 mo 31 (26-35) 41 (37-44)
Abbreviations: ATE, average treatment effect; CI, confidence interval; CrI, 
credible interval; HR, hazard ratio; IPTW, inverse probability of treatment 
weighting; OS, overall survival; SOC, standard of care.
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factors (eg, kinase domain mutations). Furthermore, post-
treatment allo-HSCT was more frequent with blinatum-
omab than external SOC (15% vs 9%). Other limitations 
include the small sample sizes of the cohorts, response 
assessment by centralized review (blinatumomab study) 
versus investigator review (external SOC), and geographic 
and chronologic differences between the study cohorts. 
The blinatumomab study was conducted in the United 
States and Europe, whereas the external SOC included 
patients enrolled at centers in Italy and Spain, with some 
patients treated 9 years before the initiation of the bli-
natumomab study. Although differences in clinical prac-
tice could be present between these cohorts (eg, the use 
of newer TKIs such as ponatinib and nilotinib), general 
practice patterns for ALL over time and between regions 
were not dramatically different. Treatment with TKIs 
and chemotherapies were standard treatment options. 
Selecting for specific qualifying salvage therapies may 
have introduced additional bias.
In conclusion, the results from the PSA reported 
here suggest that blinatumomab improves treatment out-
comes in patients with r/r Ph+ ALL in comparison with 
external SOC. These data further support blinatumomab 
as a treatment option for patients with r/r Ph+ ALL.
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